Načítá se...
Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
Immune checkpoint inhibitors (ICIs) belong to a new group of anticancer drugs targeting T-cell proteins involved in the activation of immune response toward malignancies. Their introduction into clinical practice was a milestone in modern cancer treatment. However, the significant advantage of ICIs...
Uloženo v:
| Vydáno v: | Endocr Connect |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Bioscientifica Ltd
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7576644/ https://ncbi.nlm.nih.gov/pubmed/33064663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EC-20-0342 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|